Bolt Biotherapeutics (FRA:6LP0) Other Operating Expense: €0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6LP0 Bolt Biotherapeutics Inc FRA:6LP0
53 GF Score
Price €5.18
GF Value €11.17
! 4 Warning Signs
View Full Analysis

What is Bolt Biotherapeutics Other Operating Expense?

Bolt Biotherapeutics FRA:6LP0 53 Other Operating Expense is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:6LP0 with a GF Score™ of 53/100 and a GF Value™ of €11.17. The stock has 4 warning signs investors should review.

Bolt Biotherapeutics's Other Operating Expense for the three months ended in Mar. 2026 was €0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Bolt Biotherapeutics's quarterly Other Operating Expense stayed the same from Sep. 2025 (€0.00 Mil) to Dec. 2025 (€0.00 Mil) but then increased from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€0.00 Mil).

Bolt Biotherapeutics's annual Other Operating Expense stayed the same from Dec. 2023 (€-0.00 Mil) to Dec. 2024 (€-0.00 Mil) but then increased from Dec. 2024 (€-0.00 Mil) to Dec. 2025 (€0.00 Mil).

Bolt Biotherapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Bolt Biotherapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bolt Biotherapeutics Other Operating Expense Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial -0.00 0.00 -0.00 -0.00 0.00

Bolt Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 0.00
FRA:6LP0
53GF Score
Bolt Biotherapeutics Inc FRA:6LP0
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bolt Biotherapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of €0.00 Mil mean?
Bolt Biotherapeutics (FRA:6LP0) has a Other Operating Expense of €0.00 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Bolt Biotherapeutics and its competitors.
Is Bolt Biotherapeutics' Other Operating Expense too high?
Bolt Biotherapeutics' current Other Operating Expense is €0.00 Mil. Overall, Bolt Biotherapeutics has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' Other Operating Expense compare to AIM and ERNA?
Bolt Biotherapeutics' Other Operating Expense of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Bolt Biotherapeutics and its competitors. Bolt Biotherapeutics's current Other Operating Expense is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Bolt Biotherapeutics (FRA:6LP0) has a current Other Operating Expense of €0.00 Mil. The stock's GF Value™ is €11.17, compared to a current price of €5.18 — trading 53.6% below its estimated fair value. The current Other Operating Expense is €0.00 Mil. Bolt Biotherapeutics' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Bolt Biotherapeutics (FRA:6LP0), the current Other Operating Expense is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bolt Biotherapeutics (FRA:6LP0) Overvalued in 2026?

Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued. The current stock price of €5.18 is trading 53.6% below its estimated GF Value™ of €11.17.

Key valuation signals for FRA:6LP0:

  • Other Operating Expense: €0.00 Mil
  • GF Value™: €11.17 vs. price of €5.18 (53.6% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the FRA:6LP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bolt Biotherapeutics Business Description

Other Exchanges BOLT:USA
Address 900 Chesapeake Drive, Redwood City, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
53GF Score

Get the complete analysis for FRA:6LP0

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.18
Price
€11.17
GF Value